Moreover, sPD-L1 was also associated with a poor prognosis among patients treated with anti-CTLA4 for a melanoma, suggesting that the implications of this soluble biomarker extend beyond its interactions with mPD-1/PD-L1 [54]. This evidence concerns the gene CTLA4 and melanoma.